High Insurance Coverage and Financial Support for Effective Cancer Drugs in I.R. Iran

Background: In recent years, financial coverage and availability of new and expensive cancer drugs have changed into one of the challenges of the health system, especially in low-income and middle-income countries,. We studied the availability ofanticancer drugs, insurance coverage and the financial...

Full description

Saved in:
Bibliographic Details
Published in:Basic and clinical cancer research 2018-07, Vol.10 (3)
Main Authors: Alireza Darrudi, Rajabali Daroudi
Format: Article
Language:English
Subjects:
Accessibility
cancer drugs
financial burden
insurance coverage
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: In recent years, financial coverage and availability of new and expensive cancer drugs have changed into one of the challenges of the health system, especially in low-income and middle-income countries,. We studied the availability ofanticancer drugs, insurance coverage and the financial burden of these drugs in Iran. Methods: In this cross-sectional descriptive study, first, we listed effective cancer drugs according to the World Health Organization’s Model List of Essential Medicinesand previous studies. Then, we evaluated financial burden of these drugs byusing the available data in Iran pharmaceutical Pharmacopoeia, the national pharmaceuticalsales statistics database (pharmaceutical Amarnameh), and inquiry of the insurance organizations, the availability, insurance coverage in Iran. Excel softwarewas used for data analysis. Results: All of the medicines incorporated into the latest version of the WHO Model List of Essential Medicines were available in Iran, and, except for Bendamustine and Anastrazole all medicines were covered by insurance. In addition, of the 19 drugs,those were not on the WHO Model List of Essential Medicines, there were sevendrugs in Iran, insurance covered that six drugs. The total Dollar sales of the studied cancer drugs amounted to US$350.85 million in 2015 and US$384.96 million in 2016. Conclusion: It seems that the status of access to effective cancer drugs in Iran is better than many low and middle-income countries. However, since the cost of cancerdrugs is rising, health policy makers inevitably need to prioritize cancer drugs by using the results of health technology assessment methods and provide patients withaccess to drugs that are cost-effective in order to the optimal allocation of limited resources and provide maximum access to cancer drugs throughout the country.
ISSN:2228-6527
2228-5466